Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...

Summit Therapeutics (SMMT) enters a clinical trial collaboration to evaluate its cancer drug, ivonescimab, in combination with Pfizer (PFE) antibody drug conjugates across multiple solid tumor ...

This makes ROR-1 an attractive therapeutic target for anti-cancer drug development. RB-164 employs a novel Fc-silenced monoclonal antibody targeting ROR-1, site specific conjugation to deliver a ...

ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...

pneumonitis 1 week after completing craniospinal irradiation, ADC infusions resumed; two weeks later, the patient was admitted for pneumonia Possible ADC: Antibody-drug conjugate; RT: Radiotherapy.

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.